A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system - PubMed (original) (raw)
doi: 10.1002/ijgo.13068. Epub 2019 Dec 11.
Affiliations
- PMID: 31777949
- DOI: 10.1002/ijgo.13068
A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system
Mariana Fava et al. Int J Gynaecol Obstet. 2020 Apr.
Abstract
Objective: To assess the efficacy of ulipristal acetate (UPA) for reducing abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system (LNG-IUS).
Methods: A randomized, double-blind, placebo-controlled pilot study conducted from September 1, 2016 to September 30, 2018, at the University of Campinas, Brazil. LNG-IUS users reporting prolonged or frequent uterine bleeding for at least 1 year were randomized to receive 5 mg UPA per day for 5 days or placebo at an identical regimen. Bleeding was recorded for 90 days after treatment began and was compared between the groups.
Results: Of 94 eligible women, 64 with abnormal bleeding associated with LNG-IUS use declined treatment or device removal after counselling regarding anticipated bleeding patterns. For the 25 study participants, differences were nonsignificant between the UPA and placebo groups for number of days before bleeding stopped and days free of bleeding; however, UPA users displayed a trend for shorter duration before bleeding stopped and longer time free of bleeding. A similar trend for mean number of bleeding days at 30-, 60-, and 90-day follow-up was observed.
Conclusion: A nonsignificant trend in reduction of abnormal bleeding was observed among LNG-IUS users taking 5 mg UPA per day for 5 days compared with placebo; however, further research is needed. CLINICALTRIALS.GOV: NCT03186586.
Keywords: Abnormal bleeding; Levonorgestrel intrauterine system; Randomized clinical trial; Treatment; Ulipristal acetate.
© 2019 International Federation of Gynecology and Obstetrics.
Comment in
- Excerpts from the World Medical Literature.
Ziegler C. Ziegler C. J Obstet Gynaecol Can. 2020 Sep;42(9):1073-1075. doi: 10.1016/j.jogc.2020.05.010. J Obstet Gynaecol Can. 2020. PMID: 32900455 Free PMC article. No abstract available.
Similar articles
- Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J, Heikinheimo O, Lähteenmäki P, Suhonen S. Kaislasuo J, et al. Hum Reprod. 2015 Jul;30(7):1580-8. doi: 10.1093/humrep/dev102. Epub 2015 May 19. Hum Reprod. 2015. PMID: 25990577 - Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
Papaikonomou K, Kopp Kallner H, Söderdahl F, Gemzell-Danielsson K. Papaikonomou K, et al. Hum Reprod. 2018 Nov 1;33(11):2002-2009. doi: 10.1093/humrep/dey296. Hum Reprod. 2018. PMID: 30295731 Clinical Trial. - Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby A, Hussain M, Rishworth JR, Rees MC. Lethaby A, et al. Cochrane Database Syst Rev. 2015 Apr 30;(4):CD002126. doi: 10.1002/14651858.CD002126.pub3. Cochrane Database Syst Rev. 2015. PMID: 25924648 Updated. Review. - Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J, Konje JC, Hickey M. Chin J, et al. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007245. doi: 10.1002/14651858.CD007245.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821400 Updated. Review.
Cited by
- Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use.
Christelle K, Norhayati MN, Jaafar SH. Christelle K, et al. Cochrane Database Syst Rev. 2022 Aug 26;8(8):CD006034. doi: 10.1002/14651858.CD006034.pub3. Cochrane Database Syst Rev. 2022. PMID: 36017945 Free PMC article. Review. - The use of a short course of Ulipristal Acetate for acute abnormal uterine bleeding in women without uterine fibroids.
Lambrecht I, Van den Bosch T. Lambrecht I, et al. Facts Views Vis Obgyn. 2023 Jun;15(2):99-105. doi: 10.52054/FVVO.15.2.078. Facts Views Vis Obgyn. 2023. PMID: 37436045 Free PMC article. - U.S. Selected Practice Recommendations for Contraceptive Use, 2024.
Curtis KM, Nguyen AT, Tepper NK, Zapata LB, Snyder EM, Hatfield-Timajchy K, Kortsmit K, Cohen MA, Whiteman MK; Contributors. Curtis KM, et al. MMWR Recomm Rep. 2024 Aug 8;73(3):1-77. doi: 10.15585/mmwr.rr7303a1. MMWR Recomm Rep. 2024. PMID: 39106301 Free PMC article.
References
REFERENCES
- Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann N Y Acad Sci. 1991;626:43-49.
- Sitruk-Ware R, Inki P. The levonorgestrel intrauterine system: Long-term contraception and therapeutic effects. Womens Health (Lond). 2005;1:171-182.
- Pakarinen P, Luukkainen T, Laine H, Lähteenmäki P. The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood circulation. Hum Reprod. 1995;10:2390-2394.
- Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel. Contraception. 2007;6(Suppl):S93-S98.
- Carvalho NM, Chou V, Modesto W, Margatho D, Garcia EAL, Bahamondes L. Relationship between user satisfaction with the levonorgestrel-releasing intrauterine system and bleeding patterns. J Obstet Gynecol Res. 2017;43:1732-1737.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous